scispace - formally typeset
R

Robert Elling

Researcher at Novartis

Publications -  8
Citations -  637

Robert Elling is an academic researcher from Novartis. The author has contributed to research in topics: Internal medicine & Lipid A. The author has an hindex of 7, co-authored 7 publications receiving 466 citations.

Papers
More filters
Journal ArticleDOI

Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.

TL;DR: A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines.
Journal ArticleDOI

Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.

TL;DR: This work structurally and mechanistically characterize LpxM, providing insights that may enable the targeted discovery of inhibitors that prevent lipid A maturation, and describes a high-throughput, label-free mass spectrometric assay to characterize acyltransferase enzymatic activity.
Journal ArticleDOI

Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.

TL;DR: Imidazopyridine compound 1, a potent, selective, and orally available pan-PI3K inhibitor, was further optimized in order to achieve efficacy in a PTEN-deleted A2780 ovarian cancer mouse xenograft model.